BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker sine globale mobilitetskompetencer med tilføjelsen af Courdid BV10.6.2026 22:05:00 CEST | Pressemeddelelse
Andersen Global har indgået en samarbejdsaftale med Courdid BV, som er et hollandsk konsulentfirma inden for global mobilitet, hvilket yderligere styrker organisationens rådgivningskapacitet for internationale arbejdsstyrker og expats. Courdid BV blev grundlagt for næsten to årtier siden og tilbyder en bred vifte af rådgivningstjenester inden for lønsums- og lønskat, expatbeskatning, lønudbetaling, immigration samt employer of record-løsninger. Virksomheden samarbejder med multinationale arbejdsgivere, offentlige institutioner og professionelle serviceudbydere om at levere praktisk og skræddersyet rådgivning om komplekse internationale arbejdsstyrkeforhold – kendetegnet ved en kundeorienteret tilgang, der prioriterer tilgængelighed og personlig service. "Vi bestræber os på at være praktiske og relevante for vores klienter, særligt inden for områder, der ofte er unødigt komplekse," siger Jean-Paul van ’t Hof, der er administrerende partner i Courdid BV. "Ved at blive en samarbejdende vi
TestMu AI Announces Day-Zero Support for macOS Golden Gate and iOS 27 Beta Following WWDC 202610.6.2026 21:52:00 CEST | Press release
Developers can now test websites, web applications, and mobile apps on Apple's latest operating systems before their public release TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced day-zero support for Apple's newly unveiled operating systems, macOS Golden Gate and iOS 27 Beta, across its cloud testing platform. Announced at Apple's Worldwide Developers Conference (WWDC) 2026, macOS Golden Gate and iOS 27 introduce significant platform updates that will impact application compatibility, user experience, and performance. Both operating systems are now available for testing on TestMu AI, the same day Apple released its beta versions, allowing engineering teams to identify issues months before the stable rollout reaches millions of users worldwide. macOS Golden Gate is available through the TestMu AI Real Time Testing platform, while iOS 27 Beta is available on TestMu AI Real Device Cloud across the latest iPhones and i
Pure Lithium Corporation Named World Economic Forum Technology Pioneer10.6.2026 20:10:00 CEST | Press release
Lithium metal battery innovator joins a select global cohort of 100 pioneering companies shaping the future of energy and advanced materials Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the company has been selected as a 2026 Technology Pioneer by the World Economic Forum. Launched in 2000, the Technology Pioneers is a leading community for companies from around the world that are shaping the future through breakthrough technologies and innovations. These companies are selected for their potential to have a significant impact on business and society and are invited to engage with public and private sector leaders through the World Economic Forum’s global platform. “We are delighted to be selected as a World Economic Forum Technology Pioneer. I would like to express my gratitude to the World Economic Forum for this honor,” said Pure Lithium Founder, Chairman and CEO, Emilie Bodoin. “Pure Lithium’s selection is a testament t
Visa Partners with OpenAI to Power the Next Generation of AI Commerce10.6.2026 20:00:00 CEST | Press release
New collaboration brings Visa’s global payment networkto one of the largest AI platforms and aims to support seamless, secure transactions and broader AI-powered use cases across commerce environments supported by agents Visa (NYSE: V) today announced a strategic collaboration with OpenAI to enable secure Visa payments within agentic commerce, enabling seamless and trusted payments across OpenAI. The companies made the announcement at the Visa Payments Forum in San Francisco. Through the partnership, Visa will provide its global network, credentialing capabilities and security infrastructure to support agentic commerce experiences, helping consumers and businesses interact and transact with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610422687/en/ The collaboration is part of the broader Visa Intelligent Commerce initiative, which is focused on extending secure payment capabilities into new digital environm
Visa Announces New AI, Stablecoin and Token Innovations to Power Intelligent, Programmable Commerce at Visa Payments Forum10.6.2026 20:00:00 CEST | Press release
New Agent Scoring, Agentic Registry and Large Transaction Model capabilities, stablecoin settlement and token enhancements support the next gen of digital commerce At Visa Payments Forum 2026, Visa (NYSE: V) today announced new AI, stablecoin and token capabilities designed to help clients unlock the next generation of commerce. These innovations reflect a simple objective: ensuring trust, security and control evolve alongside increasingly fast, automated and intelligent commerce experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610464331/en/ In a keynote presentation, Jack Forestell, Chief Product & Strategy Officer at Visa, outlined how two foundational shifts—artificial intelligence and stablecoins—are transforming both the front end and back end of money movement, and how Visa is enabling clients to participate. “AI is transforming the front end of commerce. Stablecoins are reshaping the back end,” said Fore
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom